Table 1 Baseline characteristics of patients
TG/HDL-C level | P | |||
|---|---|---|---|---|
T1(< 0.96) | T2(≥ 0.96, < 1.58) | T3(≥ 1.58) | ||
N | 126 | 124 | 124 | |
Age(y) | 59.46 ± 9.39 | 58.69 ± 9.07 | 57.73 ± 8.67 | 0.320 |
Male, n (%) | 81 (64.29) | 78 (62.90) | 93 (75.00) | 0.084 |
BMI, kg/m2 | 24.76 ± 2.70 | 25.83 ± 2.49 | 25.85 ± 2.71 | 0.001 |
Risk factors, n (%) | ||||
Smoking | 31 (24.60) | 35 (28.23) | 45 (36.29) | 0.118 |
Hypertension | 64 (50.79) | 74 (59.68) | 70 (56.45) | 0.359 |
Diabetes mellitus | 31 (24.60) | 32 (25.81) | 35 (28.23) | 0.803 |
Dyslipidemia | 59 (46.83) | 67 (54.03) | 78 (62.90) | 0.038 |
Laboratory results | ||||
RBC, 1012/L | 4.55 ± 0.36 | 4.59 ± 0.49 | 4.67 ± 0.45 | 0.102 |
WBC, 1012/L | 5.89 (5.00,6.96) | 6.25 (5.30,7.51) | 6.38 (5.34,7.47) | 0.185 |
PLT, 109/L | 222.00 (184.00,254.00) | 223.00 (186.75,250.25) | 212.50 (181.00,244.00) | 0.601 |
LDL-C, mmol/L | 2.11 (1.67,2.72) | 2.42 (1.76,2.83) | 2.59 (2.03,3.12) | < 0.001 |
HDL-C, mmol/L | 1.35 (1.16,1.55) | 1.10 (0.98,1.23) | 0.94 (0.85,1.05) | < 0.001 |
TC, mmol/L | 3.84 (3.31,4.63) | 3.95 (3.30,4.63) | 4.35 (3.73,5.09) | < 0.001 |
TG, mmol/L | 0.86 (0.67,1.00) | 1.37 (1.16,1.56) | 2.21 (1.85,2.75) | < 0.001 |
Glu, mmol/L | 5.50 (5.04,6.44) | 5.61 (5.24,6.52) | 5.83 (5.39,6.86) | 0.010 |
HbA1c, % | 5.80 (5.40,6.30) | 5.90 (5.57,6.62) | 5.95 (5.60,6.82) | 0.076 |
ALT, mmol/L | 21.00 (14.00,27.00) | 21.50 (15.00,30.00) | 22.00 (16.00,33.00) | 0.139 |
AST, mmol/L | 20.00 (18.00,24.00) | 21.50 (19.00,26.00) | 21.00 (17.75,25.25) | 0.126 |
TP, g/L | 69.32 ± 5.74 | 68.98 ± 5.29 | 69.51 ± 5.65 | 0.753 |
Urea, mmol/L | 5.09 (4.50,5.80) | 5.10 (4.40,6.20) | 5.40 (4.35,6.10) | 0.703 |
UA, µmol/L | 310.05 (271.35,338.32) | 315.55 (292.32,346.33) | 324.45 (299.15,361.45) | 0.012 |
Cr, µmol/L | 65.55 (56.00,72.68) | 68.00 (58.90,74.85) | 69.10 (60.93,78.03) | 0.017 |
Hcy, µmol/L | 11.25 (8.72,14.57) | 11.90 (9.38,14.45) | 12.00 (9.10,16.30) | 0.409 |
CRP, mg/L | 0.76 (0.40,1.54) | 0.91 (0.37,2.04) | 1.10 (0.69,2.42) | 0.010 |
EF, % | 65 (61,67) | 65 (62,68) | 65 (62,68) | 0.485 |
TG/HDL-C | 0.65 (0.49,0.80) | 1.25 (1.11,1.38) | 2.25 (1.91,2.75) | < 0.001 |
Procedure characteristics | ||||
FFR | 0.85 (0.83,0.88) | 0.85 (0.82,0.88) | 0.85 (0.83,0.88) | 0.729 |
LM, n (%) | 3 (2.4) | 2 (1.6) | 2 (1.6) | 0.654 |
LAD, n (%) | 90 (71.4) | 90 (72.6) | 82 (66.1) | 0.496 |
LCX, n (%) | 10 (7.9) | 12 (9.7) | 15 (12.1) | 0.543 |
RCA | 23 (18.3) | 20 (16.1) | 25 (20.2) | 0.712 |
Medication at discharge, n (%) | ||||
Aspirin | 124 (98.4) | 122 (98.4) | 124 (100) | 0.367 |
Statin | 93 (73.8) | 96 (77.4) | 104 (83.9) | 0.148 |
Ezetimibe | 17 (13.5) | 21 (16.9) | 26 (21.0) | 0.291 |
TG-lowering agents | 2 (1.6) | 4 (3.2) | 18% (6.5) | 0.120 |
β-Blocker | 54 (42.9) | 69 (55.6) | 60 (48.4) | 0.128 |
antidiabetic agents | 22 (17.5) | 27 (21.8) | 32 (25.8) | 0.277 |